| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Venous Thromboembolism | 40 | 2020 | 4273 | 3.58 | Why? |
| Anticoagulants | 54 | 2021 | 9563 | 3.30 | Why? |
| Rivaroxaban | 10 | 2018 | 467 | 2.01 | Why? |
| Venous Thrombosis | 17 | 2020 | 2739 | 1.93 | Why? |
| Heparin, Low-Molecular-Weight | 8 | 2021 | 1731 | 1.42 | Why? |
| Budd-Chiari Syndrome | 2 | 2017 | 31 | 1.35 | Why? |
| Atrial Fibrillation | 14 | 2021 | 2320 | 1.29 | Why? |
| Cerebral Veins | 2 | 2017 | 81 | 1.28 | Why? |
| Splanchnic Circulation | 4 | 2018 | 37 | 1.24 | Why? |
| Factor Xa Inhibitors | 10 | 2020 | 490 | 1.16 | Why? |
| Hemorrhage | 15 | 2021 | 3013 | 1.06 | Why? |
| Pulmonary Embolism | 15 | 2020 | 4775 | 1.06 | Why? |
| Administration, Oral | 21 | 2020 | 2340 | 1.05 | Why? |
| Intracranial Thrombosis | 2 | 2017 | 339 | 0.97 | Why? |
| Fibrinolytic Agents | 7 | 2020 | 1702 | 0.76 | Why? |
| Mesenteric Vascular Occlusion | 1 | 2017 | 43 | 0.68 | Why? |
| Antithrombins | 2 | 2020 | 353 | 0.68 | Why? |
| Stroke | 8 | 2021 | 8839 | 0.64 | Why? |
| Hashimoto Disease | 1 | 2017 | 74 | 0.63 | Why? |
| Enoxaparin | 3 | 2019 | 1064 | 0.62 | Why? |
| Neck Pain | 1 | 2017 | 126 | 0.60 | Why? |
| Portal Vein | 2 | 2018 | 193 | 0.60 | Why? |
| Vitamin K | 4 | 2020 | 263 | 0.51 | Why? |
| Thrombophilia | 4 | 2021 | 1935 | 0.48 | Why? |
| Thyroid Gland | 1 | 2017 | 516 | 0.47 | Why? |
| Blood Coagulation | 5 | 2021 | 2768 | 0.46 | Why? |
| Thiophenes | 2 | 2009 | 78 | 0.46 | Why? |
| Premedication | 1 | 2010 | 40 | 0.44 | Why? |
| Circadian Rhythm | 1 | 2017 | 607 | 0.44 | Why? |
| Thiazoles | 5 | 2018 | 496 | 0.42 | Why? |
| Morpholines | 2 | 2009 | 351 | 0.41 | Why? |
| Pulmonary Artery | 1 | 2017 | 803 | 0.40 | Why? |
| Attitude of Health Personnel | 2 | 2019 | 4741 | 0.40 | Why? |
| Thrombosis | 6 | 2021 | 7504 | 0.40 | Why? |
| Pyridines | 5 | 2018 | 680 | 0.39 | Why? |
| Thrombin | 3 | 2018 | 325 | 0.38 | Why? |
| Thromboembolism | 2 | 2020 | 2101 | 0.34 | Why? |
| Drug Administration Schedule | 6 | 2020 | 2324 | 0.32 | Why? |
| Patient Admission | 3 | 2020 | 5250 | 0.31 | Why? |
| Ambulatory Surgical Procedures | 1 | 2010 | 444 | 0.31 | Why? |
| Recurrence | 7 | 2020 | 3675 | 0.29 | Why? |
| Heparin | 5 | 2021 | 2600 | 0.28 | Why? |
| Seasons | 1 | 2017 | 4071 | 0.27 | Why? |
| Dabigatran | 4 | 2018 | 204 | 0.27 | Why? |
| Hospitalization | 7 | 2021 | 54280 | 0.26 | Why? |
| Humans | 86 | 2021 | 930598 | 0.26 | Why? |
| Internal Medicine | 2 | 2021 | 557 | 0.25 | Why? |
| Perioperative Care | 3 | 2018 | 1329 | 0.25 | Why? |
| Propensity Score | 3 | 2021 | 2690 | 0.25 | Why? |
| Disease-Free Survival | 2 | 2018 | 1654 | 0.24 | Why? |
| Neoplasms | 7 | 2019 | 17251 | 0.24 | Why? |
| Time Factors | 10 | 2019 | 31397 | 0.24 | Why? |
| Purpura, Thrombocytopenic, Idiopathic | 2 | 2021 | 645 | 0.23 | Why? |
| Platelet Aggregation Inhibitors | 4 | 2020 | 1671 | 0.22 | Why? |
| Fibrin Fibrinogen Degradation Products | 5 | 2020 | 5993 | 0.22 | Why? |
| Drug Monitoring | 2 | 2020 | 1408 | 0.21 | Why? |
| Italy | 16 | 2021 | 38444 | 0.21 | Why? |
| Stents | 2 | 2018 | 916 | 0.21 | Why? |
| Risk Factors | 17 | 2021 | 71621 | 0.21 | Why? |
| Magnetic Resonance Imaging | 1 | 2017 | 6551 | 0.20 | Why? |
| Pyridones | 4 | 2018 | 738 | 0.20 | Why? |
| Clinical Trials as Topic | 4 | 2018 | 7330 | 0.20 | Why? |
| Physicians | 1 | 2019 | 4214 | 0.20 | Why? |
| Thrombolytic Therapy | 4 | 2018 | 2218 | 0.20 | Why? |
| Warfarin | 3 | 2018 | 402 | 0.19 | Why? |
| Respiratory Insufficiency | 1 | 2020 | 7301 | 0.19 | Why? |
| Hypertension, Pulmonary | 2 | 2017 | 970 | 0.18 | Why? |
| Ultrasonography, Doppler, Color | 1 | 2018 | 107 | 0.18 | Why? |
| Treatment Outcome | 15 | 2021 | 51732 | 0.18 | Why? |
| Mobility Limitation | 1 | 2019 | 153 | 0.18 | Why? |
| Contraindications, Drug | 1 | 2019 | 281 | 0.18 | Why? |
| Female | 38 | 2021 | 380317 | 0.17 | Why? |
| Surgical Procedures, Operative | 3 | 2018 | 2662 | 0.17 | Why? |
| Male | 37 | 2021 | 367725 | 0.17 | Why? |
| Aged | 30 | 2021 | 215776 | 0.17 | Why? |
| Middle Aged | 26 | 2021 | 270681 | 0.17 | Why? |
| P-Selectin | 1 | 2018 | 224 | 0.16 | Why? |
| Drug Substitution | 1 | 2020 | 385 | 0.16 | Why? |
| Survival Rate | 3 | 2021 | 9206 | 0.16 | Why? |
| Hospital Mortality | 7 | 2021 | 22087 | 0.16 | Why? |
| Phospholipids | 1 | 2018 | 202 | 0.16 | Why? |
| Polysaccharides | 2 | 2017 | 854 | 0.16 | Why? |
| Prognosis | 8 | 2020 | 32490 | 0.16 | Why? |
| Consensus | 4 | 2018 | 6345 | 0.16 | Why? |
| Predictive Value of Tests | 3 | 2021 | 9537 | 0.15 | Why? |
| Emergency Service, Hospital | 1 | 2020 | 14232 | 0.15 | Why? |
| Ventricular Function, Right | 1 | 2018 | 388 | 0.14 | Why? |
| Pyrazoles | 4 | 2018 | 1791 | 0.14 | Why? |
| Catheterization, Peripheral | 1 | 2018 | 249 | 0.14 | Why? |
| Polypharmacy | 1 | 2017 | 347 | 0.14 | Why? |
| Risk Assessment | 6 | 2021 | 25439 | 0.14 | Why? |
| Cerebrovascular Circulation | 1 | 2017 | 340 | 0.14 | Why? |
| Pregnancy Complications, Cardiovascular | 1 | 2017 | 231 | 0.13 | Why? |
| Cell Movement | 1 | 2017 | 695 | 0.13 | Why? |
| Cardiology | 2 | 2018 | 2873 | 0.13 | Why? |
| Arthroplasty, Replacement, Knee | 2 | 2009 | 363 | 0.13 | Why? |
| Fibroblasts | 1 | 2017 | 839 | 0.13 | Why? |
| Blood Coagulation Tests | 1 | 2018 | 855 | 0.12 | Why? |
| Delphi Technique | 1 | 2017 | 1257 | 0.12 | Why? |
| Dyspnea | 1 | 2006 | 3847 | 0.12 | Why? |
| Disease Management | 4 | 2020 | 6841 | 0.12 | Why? |
| Aged, 80 and over | 13 | 2021 | 88759 | 0.12 | Why? |
| Up-Regulation | 1 | 2020 | 2249 | 0.12 | Why? |
| Prospective Studies | 9 | 2019 | 43301 | 0.12 | Why? |
| Length of Stay | 3 | 2018 | 11042 | 0.11 | Why? |
| Drug Utilization | 1 | 2017 | 619 | 0.11 | Why? |
| Percutaneous Coronary Intervention | 2 | 2018 | 3646 | 0.11 | Why? |
| Comorbidity | 5 | 2020 | 34796 | 0.11 | Why? |
| Kaplan-Meier Estimate | 2 | 2018 | 4260 | 0.11 | Why? |
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 1014 | 0.11 | Why? |
| Evidence-Based Practice | 1 | 2017 | 693 | 0.11 | Why? |
| Antiphospholipid Syndrome | 1 | 2017 | 533 | 0.11 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 2 | 2017 | 1261 | 0.11 | Why? |
| Cardiovascular Diseases | 4 | 2020 | 11497 | 0.10 | Why? |
| Thrombocytopenia | 3 | 2021 | 2093 | 0.10 | Why? |
| Cell Proliferation | 1 | 2017 | 1973 | 0.10 | Why? |
| Hemostasis | 3 | 2020 | 811 | 0.10 | Why? |
| Sex Distribution | 1 | 2017 | 2083 | 0.10 | Why? |
| Health Care Surveys | 1 | 2019 | 2942 | 0.10 | Why? |
| Cohort Studies | 8 | 2021 | 36005 | 0.10 | Why? |
| Retrospective Studies | 9 | 2021 | 105322 | 0.10 | Why? |
| Antimalarials | 1 | 2021 | 2505 | 0.09 | Why? |
| ROC Curve | 1 | 2021 | 6024 | 0.09 | Why? |
| Intermittent Pneumatic Compression Devices | 2 | 2018 | 40 | 0.09 | Why? |
| Biomarkers | 6 | 2020 | 23361 | 0.09 | Why? |
| Incidence | 6 | 2018 | 25622 | 0.09 | Why? |
| Medication Adherence | 1 | 2017 | 1270 | 0.09 | Why? |
| Inpatients | 2 | 2020 | 5161 | 0.08 | Why? |
| Thrombectomy | 1 | 2018 | 2272 | 0.08 | Why? |
| Apoptosis | 1 | 2017 | 2335 | 0.08 | Why? |
| Age Distribution | 1 | 2017 | 3567 | 0.08 | Why? |
| Vena Cava Filters | 2 | 2018 | 89 | 0.08 | Why? |
| Liver Cirrhosis | 1 | 2018 | 1810 | 0.08 | Why? |
| Cause of Death | 2 | 2018 | 4823 | 0.08 | Why? |
| Blood Coagulation Disorders | 1 | 2020 | 2040 | 0.08 | Why? |
| Adult | 13 | 2021 | 244371 | 0.08 | Why? |
| Critical Care | 5 | 2021 | 14081 | 0.07 | Why? |
| International Cooperation | 1 | 2018 | 3436 | 0.07 | Why? |
| Brain Ischemia | 1 | 2020 | 2813 | 0.07 | Why? |
| Age Factors | 4 | 2020 | 21039 | 0.07 | Why? |
| Intubation, Intratracheal | 1 | 2021 | 3962 | 0.07 | Why? |
| Odds Ratio | 1 | 2017 | 5861 | 0.07 | Why? |
| Lymphocytes | 1 | 2018 | 3056 | 0.07 | Why? |
| Double-Blind Method | 4 | 2018 | 5988 | 0.07 | Why? |
| Registries | 3 | 2018 | 12327 | 0.07 | Why? |
| Machine Learning | 1 | 2020 | 4395 | 0.07 | Why? |
| Arthroplasty, Replacement, Hip | 1 | 2009 | 403 | 0.07 | Why? |
| Confidence Intervals | 1 | 2006 | 744 | 0.06 | Why? |
| Lung Diseases | 1 | 2017 | 2361 | 0.06 | Why? |
| Coronary Artery Disease | 1 | 2018 | 2570 | 0.06 | Why? |
| Betacoronavirus | 8 | 2020 | 204454 | 0.06 | Why? |
| Societies, Medical | 4 | 2020 | 6907 | 0.06 | Why? |
| Secondary Prevention | 2 | 2017 | 762 | 0.06 | Why? |
| Survival Analysis | 3 | 2021 | 7592 | 0.06 | Why? |
| Logistic Models | 1 | 2017 | 9089 | 0.06 | Why? |
| Clinical Competence | 1 | 2017 | 3263 | 0.06 | Why? |
| Risk | 3 | 2018 | 5288 | 0.06 | Why? |
| Heart Diseases | 1 | 2018 | 3503 | 0.06 | Why? |
| Neutrophils | 1 | 2018 | 5476 | 0.05 | Why? |
| Patient Safety | 1 | 2016 | 4885 | 0.05 | Why? |
| Malawi | 1 | 2021 | 287 | 0.05 | Why? |
| Sex Factors | 1 | 2018 | 11014 | 0.05 | Why? |
| Ultrasonography | 3 | 2018 | 4409 | 0.05 | Why? |
| Randomized Controlled Trials as Topic | 2 | 2010 | 10649 | 0.05 | Why? |
| Young Adult | 4 | 2020 | 93724 | 0.05 | Why? |
| Pneumonia, Viral | 8 | 2020 | 243684 | 0.05 | Why? |
| Coronavirus Infections | 8 | 2020 | 253789 | 0.05 | Why? |
| Sensitivity and Specificity | 2 | 2020 | 22971 | 0.05 | Why? |
| Glycosaminoglycans | 1 | 2020 | 140 | 0.05 | Why? |
| Immunocompetence | 1 | 2021 | 280 | 0.05 | Why? |
| Aftercare | 2 | 2020 | 1637 | 0.05 | Why? |
| Models, Statistical | 1 | 2017 | 5312 | 0.05 | Why? |
| Diagnostic Techniques, Cardiovascular | 1 | 2020 | 144 | 0.05 | Why? |
| Postoperative Complications | 1 | 2018 | 5861 | 0.05 | Why? |
| Observational Studies as Topic | 2 | 2017 | 1887 | 0.05 | Why? |
| Malta | 1 | 2018 | 70 | 0.05 | Why? |
| Respiration, Artificial | 2 | 2021 | 22116 | 0.05 | Why? |
| Stockings, Compression | 1 | 2018 | 20 | 0.05 | Why? |
| Factor Xa | 1 | 2018 | 113 | 0.04 | Why? |
| Renal Insufficiency, Chronic | 1 | 2012 | 2654 | 0.04 | Why? |
| Follow-Up Studies | 3 | 2017 | 17020 | 0.04 | Why? |
| Food-Drug Interactions | 1 | 2017 | 24 | 0.04 | Why? |
| Inflammation | 1 | 2020 | 13255 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2021 | 12447 | 0.04 | Why? |
| Europe | 3 | 2018 | 12702 | 0.04 | Why? |
| Anesthesiology | 2 | 2018 | 1163 | 0.04 | Why? |
| Ventricular Fibrillation | 1 | 2018 | 126 | 0.04 | Why? |
| Drug Design | 1 | 2009 | 2627 | 0.04 | Why? |
| Perfusion Imaging | 1 | 2018 | 199 | 0.04 | Why? |
| Blood Coagulation Factors | 1 | 2018 | 223 | 0.04 | Why? |
| Blood Loss, Surgical | 1 | 2018 | 211 | 0.04 | Why? |
| Comparative Effectiveness Research | 1 | 2017 | 178 | 0.04 | Why? |
| Perfusion | 1 | 2017 | 254 | 0.04 | Why? |
| Postoperative Hemorrhage | 1 | 2018 | 183 | 0.04 | Why? |
| Pulmonary Edema | 1 | 2020 | 430 | 0.04 | Why? |
| Arginine | 1 | 2018 | 377 | 0.04 | Why? |
| Benzamides | 1 | 2018 | 421 | 0.04 | Why? |
| Piperazines | 1 | 2018 | 445 | 0.04 | Why? |
| Perioperative Period | 1 | 2017 | 276 | 0.04 | Why? |
| Clinical Decision-Making | 2 | 2021 | 3755 | 0.04 | Why? |
| Proportional Hazards Models | 2 | 2018 | 6543 | 0.04 | Why? |
| Global Health | 1 | 2018 | 13911 | 0.04 | Why? |
| Product Surveillance, Postmarketing | 1 | 2017 | 189 | 0.04 | Why? |
| Databases, Pharmaceutical | 1 | 2017 | 345 | 0.03 | Why? |
| Prevalence | 1 | 2017 | 25773 | 0.03 | Why? |
| Animals | 3 | 2020 | 78931 | 0.03 | Why? |
| Lung | 2 | 2020 | 31049 | 0.03 | Why? |
| Glomerular Filtration Rate | 1 | 2020 | 1262 | 0.03 | Why? |
| Societies, Scientific | 1 | 2017 | 414 | 0.03 | Why? |
| In Vitro Techniques | 1 | 2017 | 1027 | 0.03 | Why? |
| Critical Illness | 1 | 2018 | 17281 | 0.03 | Why? |
| Evidence-Based Medicine | 2 | 2017 | 3228 | 0.03 | Why? |
| Review Literature as Topic | 1 | 2017 | 387 | 0.03 | Why? |
| European Union | 1 | 2018 | 565 | 0.03 | Why? |
| Expert Testimony | 1 | 2017 | 658 | 0.03 | Why? |
| Reference Standards | 1 | 2017 | 1163 | 0.03 | Why? |
| Medication Therapy Management | 1 | 2017 | 312 | 0.03 | Why? |
| Coronary Thrombosis | 1 | 2018 | 433 | 0.03 | Why? |
| Cluster Analysis | 1 | 2021 | 3001 | 0.03 | Why? |
| Diagnosis, Computer-Assisted | 1 | 2017 | 436 | 0.03 | Why? |
| Chemical and Drug Induced Liver Injury | 1 | 2016 | 451 | 0.03 | Why? |
| Denmark | 1 | 2018 | 2654 | 0.03 | Why? |
| Coronavirus | 1 | 2020 | 18339 | 0.03 | Why? |
| Decision Support Techniques | 1 | 2018 | 903 | 0.03 | Why? |
| Pandemics | 8 | 2020 | 389249 | 0.03 | Why? |
| Patient Discharge | 2 | 2018 | 5696 | 0.02 | Why? |
| Aspirin | 1 | 2018 | 1043 | 0.02 | Why? |
| Patient Readmission | 1 | 2018 | 1543 | 0.02 | Why? |
| Practice Guidelines as Topic | 3 | 2017 | 15421 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2018 | 3776 | 0.02 | Why? |
| Recombinant Proteins | 1 | 2018 | 3786 | 0.02 | Why? |
| Transcatheter Aortic Valve Replacement | 1 | 2017 | 839 | 0.02 | Why? |
| Computed Tomography Angiography | 1 | 2018 | 2153 | 0.02 | Why? |
| Coronary Angiography | 1 | 2018 | 2275 | 0.02 | Why? |
| Regression Analysis | 1 | 2015 | 2484 | 0.02 | Why? |
| Point-of-Care Testing | 1 | 2020 | 2782 | 0.02 | Why? |
| Cells, Cultured | 1 | 2017 | 5835 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.02 | Why? |
| Gene Expression Profiling | 1 | 2017 | 3788 | 0.02 | Why? |
| Kidney Diseases | 1 | 2016 | 1434 | 0.02 | Why? |
| Health Resources | 1 | 2018 | 2592 | 0.02 | Why? |
| Acute Disease | 1 | 2017 | 6029 | 0.02 | Why? |
| Patient Satisfaction | 1 | 2017 | 2517 | 0.02 | Why? |
| C-Reactive Protein | 1 | 2020 | 7972 | 0.02 | Why? |
| Saliva | 1 | 2020 | 4679 | 0.02 | Why? |
| Patient Care Team | 1 | 2018 | 3556 | 0.02 | Why? |
| Travel | 1 | 2021 | 7220 | 0.02 | Why? |
| Phylogeny | 1 | 2021 | 13341 | 0.02 | Why? |
| Germany | 1 | 2017 | 9196 | 0.01 | Why? |
| Kidney | 1 | 2016 | 3648 | 0.01 | Why? |
| Severity of Illness Index | 2 | 2021 | 48226 | 0.01 | Why? |
| Reproducibility of Results | 1 | 2018 | 11304 | 0.01 | Why? |
| Liver Diseases | 1 | 2017 | 2698 | 0.01 | Why? |
| Research Design | 1 | 2017 | 5830 | 0.01 | Why? |
| Anti-Inflammatory Agents | 1 | 2020 | 6153 | 0.01 | Why? |
| Mutation | 1 | 2021 | 12376 | 0.01 | Why? |
| Ambulatory Care | 1 | 2017 | 4947 | 0.01 | Why? |
| Mass Screening | 1 | 2020 | 8005 | 0.01 | Why? |
| Algorithms | 1 | 2017 | 7346 | 0.01 | Why? |
| Acute Kidney Injury | 1 | 2020 | 5762 | 0.01 | Why? |
| Databases, Factual | 1 | 2012 | 6248 | 0.01 | Why? |
| Biomedical Research | 1 | 2018 | 5270 | 0.01 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 9335 | 0.01 | Why? |
| Kidney Failure, Chronic | 1 | 2012 | 3222 | 0.01 | Why? |
| Quality of Life | 1 | 2017 | 9820 | 0.01 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.01 | Why? |
| Pregnancy | 1 | 2017 | 23879 | 0.01 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.01 | Why? |
| Intensive Care Units | 1 | 2018 | 29594 | 0.01 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.01 | Why? |
| United States | 1 | 2017 | 46150 | 0.01 | Why? |
| Adolescent | 1 | 2020 | 86841 | 0.01 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2012 | 53120 | 0.00 | Why? |